The involvement of HMGB1/RAGE in particular, as well as HMGB1/TLR interactions, in tumor progression in both the clinical and experimental settings is now well recognized, and may involve distinct signaling pathways in different types of malignancies. This evidence concerns the gene AGER and neoplasm.